Levomenthol
As of the edition of 20 October 2026, Levomenthol is a small molecule: marketed, first approved in 1945 (CH); acts on TRPM8.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2010
- Kind
- Small molecule
- Brand name
- Dul-X Classic
- First approved
- 30 November 1945 (CH)
- Approvals on record
- 6 in 4 regions
- Holder of the most recent approval
- Reckitt Benckiser; 4 holders in all
- Registered trials
- 6, 1 stopped early
- Disease areas
- Lungs and airways; Skin and connective tissue; Immune system; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route B because of this drug.
Companies on route B for this drug
In the product2 companies are on route B because of Levomenthol.
See the 2 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TRPM8 | Transient receptor potential cation channel subfamily M member 8 | Q7Z2W7 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 0 | 0 | 1 |
| Phase 2 | 3 | 1 | 2 | 0 |
| Phase 3 | 1 | 0 | 0 | 0 |
| All trials | 6 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Reckitt Benckiser | Applicant | 2006 to now |
| Nihon Pharmaceutical | Applicant | 2010 to now |